We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we'll assume that you are OK with this.     OK  No, I would like to know more...
Home / About Novasep / Media & Events / Press releases

Press releases

Novasep launches Hipersep® Process M, its new commercial-scale HPLC chromatography system, for the development and production of pharmaceuticals

Novasep launches Hipersep® Process M, its new commercial-scale HPLC chromatography system, for the development and production of pharmaceuticals

20 Oct 2021

Novasep continues to lead and innovate in the development and production of pharmaceutical molecules and announces the launch of a new industrial-scale HPLC system that is faster, safer, and more productive than ever: Hipersep® Process M

• A new unit designed for high-pressure chromatography up to 100 bars, suitable for purification processes requiring high temperatures (up to 85°C)
• A wide range of flow rates (20 to 500 l/h) for more flexibility
• A sanitary design for faster, easier, and more efficient cleaning


PharmaZell and Novasep enter into exclusive negotiations in new drive to create a technology-driven leader for complex small molecules and ADCs of global scale.

Novasep signs a manufacturing services agreement with Exelixis for a next-generation ADC

Novasep signs a manufacturing services agreement with Exelixis for a next-generation ADC

06 Jul 2021

• The agreement covers the cGMP clinical manufacturing of a next-generation ADC drug candidate
• Novasep’s Le Mans site, in France, has already manufactured the ADC for Exelixis’ ongoing phase 1 clinical trial
• Novasep leverages its ADC bioconjugation expertise and process development capabilities in support of promising new cancer treatments


Novasep invests €6.1 million to upgrade its manufacturing facility for Active Pharmaceutical Ingredients at its Mourenx site

Novasep invests €6.1 million to upgrade its manufacturing facility for Active Pharmaceutical Ingredients at its Mourenx site

24 Jun 2021





• Novasep continues its investment strategy by upgrading its API manufacturing facility at its Mourenx site, increasing its flexibility and competitiveness
• A €6.1 million investment will be made over 3 years
• This investment has been selected by the French Government to be supported by ‘France Relance’, the post-Covid recovery plan
• 7 full-time jobs to be created


Following the repayment in full of its euro-denominated notes due 2022, novasep announces its intent to pay an interim dividend on or around june 30, 2021

Le Campus Biotech Digital s’allie à Atos, IBM et Microsoft pour le développement d’une plateforme de formation unique au monde

Le Campus Biotech Digital s’allie à Atos, IBM et Microsoft pour le développement d’une plateforme de formation unique au monde

27 May 2021

Une nouvelle étape pour l’avancée d’un projet innovant et structurant au service de la Bioproduction de santé française


Novasep expands its HPAPI manufacturing capacity in Le Mans for innovative cancer therapies

Novasep expands its HPAPI manufacturing capacity in Le Mans for innovative cancer therapies

12 May 2021

• Novasep continues to consolidate its position as a leading CDMO for the production of innovative and targeted molecules to treat cancer by investing in additional capacity
• Responds to increasing customer demand for manufacturing services for Antibody Drug Conjugates (ADCs)
• More than 30 full-time jobs to be created


Novasep announces strong growth in 2020, in an exceptional context, demonstrating the robustness of its strategic model

Novasep announces strong growth in 2020, in an exceptional context, demonstrating the robustness of its strategic model

05 May 2021

• The Group recorded sales of €394M (+46%) and an EBITDA of €63M (+174%)
• Novasep has now completed its Rise-2 strategic plan, a full two years ahead of schedule
• Full deleveraging is in progress following the divestment of the Viral Vector Manufacturing Business in early 2021


Novasep announces results of notes offer for its outstanding euro-denominated unsecured exchange notes due 2022

Novasep announces results of notes offer for its outstanding euro-denominated unsecured exchange notes due 2022

29 Apr 2021

Novasep Holding S.A.S. (“Novasep”) has today announced the results of its offer to purchase (the “Notes Offer”) any and all of its outstanding euro-denominated unsecured exchange notes due 2022 (the “Notes”).


Novasep announces notes offer for its outstanding euro-denominated unsecured exchange notes due 2022 and concurrent optional redemption

Novasep announces notes offer for its outstanding euro-denominated unsecured exchange notes due 2022 and concurrent optional redemption

01 Apr 2021

Novasep Holding S.A.S. (“Novasep”) has today commenced an offer to purchase (the “Notes Offer”) any and all of its outstanding euro-denominated unsecured exchange notes due 2022 (the “Notes”).



You can stay on this page and select more documents or you can directly download the brochure(s) you selected

Your brochure is ready!

X

You can stay on this page and select more documents or you can directly download the brochure(s) you selected

Give us your feedback!